Biomia, the first company spun out from BioInnovation Institute’s Bio Studio programme, has secured $3 million in pre-seed financing from an international syndicate of investors. Biomia says it plans to use the investment to accelerate its development of plant-inspired natural and new-to-nature halogenated small molecule drug candidates and further build its biosynthetic manufacturing platform. Chief […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!